Literature DB >> 21664922

Synergistic anti-allodynic effects of nociceptin/orphanin FQ and cannabinoid systems in neuropathic mice.

Ozgur Gunduz1, Hakan C Karadag, Ahmet Ulugol.   

Abstract

Combinations of analgesics from different classes are commonly used in the management of chronic pain. The goal is to enhance pain relief together with the reduction of side effects. The present study was undertaken to examine the anti-allodynic synergy resulting from the combination of WIN 55,212-2, a cannabinoid CB1 receptor agonist, and JTC-801, a nociceptin/orphanin FQ receptor antagonist, on neuropathic pain. Mice were tested for behavioral effects before and 2-4 weeks after the surgery, in which a partial tight ligation of the sciatic nerve was made. Nerve injury-induced mechanical allodynia was assessed with Dynamic Plantar Aesthesiometer, and a hot/cold plate was used to assess cold allodynia. Both WIN 55,212-2 and JTC-801 produced dose-dependent mechanical and cold anti-allodynic effects. As shown by isobolographic analysis, WIN 55,212-2/JTC-801 combinations interacted synergistically at all three ratios studied in the mechanical allodynia assay. In conclusion, co-administration of a cannabinoid with a nociceptin/orphanin FQ receptor antagonist resulted in a synergistic interaction, which may have utility in the pharmacological treatment of neuropathic pain.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664922     DOI: 10.1016/j.pbb.2011.05.029

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

Review 1.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

2.  Attenuation of serotonin-induced itch responses by inhibition of endocannabinoid degradative enzymes, fatty acid amide hydrolase and monoacylglycerol lipase.

Authors:  Nurcan Calimli Tosun; Ozgur Gunduz; Ahmet Ulugol
Journal:  J Neural Transm (Vienna)       Date:  2014-06-11       Impact factor: 3.575

Review 3.  The endocannabinoid system as a potential therapeutic target for pain modulation.

Authors:  Ahmet Ulugöl
Journal:  Balkan Med J       Date:  2014-06-01       Impact factor: 2.021

4.  The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.

Authors:  Molly S Crowe; Catheryn D Wilson; Emma Leishman; Paul L Prather; Heather B Bradshaw; Matthew L Banks; Steven G Kinsey
Journal:  Br J Pharmacol       Date:  2017-11-20       Impact factor: 8.739

5.  Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder.

Authors:  Y Zhang; C D Simpson-Durand; K M Standifer
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

6.  Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone.

Authors:  Pinar Elmas; Ahmet Ulugol
Journal:  J Neural Transm (Vienna)       Date:  2013-06-20       Impact factor: 3.575

7.  Non-opioid Analgesics and the Endocannabinoid System

Authors:  Ruhan Deniz Topuz; Özgur Gündüz; Çetin Hakan Karadağ; Ahmet Ulugöl
Journal:  Balkan Med J       Date:  2020-06-19       Impact factor: 2.021

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.